Which drug cuts opioid use after bariatric surgery? new trial aims to find out
NCT ID NCT06738043
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests two different drugs—dexmedetomidine and low-dose ketamine—given during weight-loss surgery to see which one reduces pain and the need for morphine afterward. Ninety adults having bariatric surgery will be randomly assigned to one of the two drugs or a placebo. The goal is to find a safer, more effective way to manage pain without relying on opioids.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Dexmedetomidine and ketamine (given as infusions during surgery)
What this could lead to
If one drug works better, it could offer a safer way to manage pain after weight-loss surgery, reducing the need for strong opioids.
What could go wrong
This is a small, early-stage trial (90 people) comparing two drugs already in use. It may not show a clear winner, and results may not apply to all surgery patients.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••